Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C13H18ClN3O4S2 |
| Molecular Weight | 379.883 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(CC3CCCC3)NS(=O)(=O)C2=C1
InChI
InChIKey=BKYKPTRYDKTTJY-UHFFFAOYSA-N
InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)
| Molecular Formula | C13H18ClN3O4S2 |
| Molecular Weight | 379.883 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P55017 Gene ID: 6559.0 Gene Symbol: SLC12A3 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NAVIDREX Approved UseNavidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases. |
|||
| Primary | NAVIDREX Approved UseNavidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases. |
|||
| Primary | NAVIDREX Approved UseNavidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Enalapril-related cholestatic jaundice. | 1990-04 |
|
| Is nifedipine a suitable first-line treatment for essential hypertension in general practice? | 1987-11 |
|
| Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. | 1987-04 |
|
| Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. | 1985-09 |
|
| Effect of long-term diuretic treatment on body-potassium in heart-disease. | 1976-11-13 |
|
| Letter: Paradoxical effect of pindolol. | 1975-07-19 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 19:47:42 GMT 2025
by
admin
on
Wed Apr 02 19:47:42 GMT 2025
|
| Record UNII |
T7817XC41U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
96783-05-0
Created by
admin on Wed Apr 02 19:47:42 GMT 2025 , Edited by admin on Wed Apr 02 19:47:42 GMT 2025
|
PRIMARY | |||
|
T7817XC41U
Created by
admin on Wed Apr 02 19:47:42 GMT 2025 , Edited by admin on Wed Apr 02 19:47:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
